Brief: Pharmena To Extend Strategy By Product Addressed At Covid-19 Patients With Complications
July 15 (Reuters) - Pharmena SA PHR.WA :
* PLANS TO EXTEND STRATEGY BY PRODUCT ADDRESSED AT COVID-19
PATIENTS WITH COMPLICATIONS
* DECISION IS DUE TO POSITIVE RESEARCH RESULTS REGARDING
1-MNA
IMPACT ON COVID-19 PATIENTS WITH COMPLICATIONS
Source text for Eikon: ID:nEM1L0DMVa
Further company coverage: PHR.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Pharmena SA
See all newsBrief: Pharmena Makes Cession Of Rights And Obligations From Unit Menavitin
Brief: Pharmena Signs Two Distribution Deals For US, Canada And Mexico Markets
Brief: Pharmena 9-Month Net Loss Narrows To 0.7 Mln Zlotys
Brief: Pharmena Plans To Separate Dermocosmetic Business
Brief: Pharmena H1 Net Loss Narrows To 0.6 Mln Zlotys